From MarketBeat:

Maravai LifeSciences Holdings, Inc. experienced an unusual increase in options trading activity on Wednesday, with 1,002 put options being purchased – up approximately 1,791% from the typical daily volume of 53 put options.

Despite some moderate ratings changes, Maravai LifeSciences saw a slight trading increase of 0.3% on the NASDAQ on Thursday, with a stock opening at $6.66.

Q3 earnings results for Maravai LifeSciences came in better than expected at ($0.02) per share, with revenue of $66.87 million for the quarter. Sell-side analysts anticipate that Maravai LifeSciences will post 0.1 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of Maravai LifeSciences, including Zions Bancorporation N.A., Comerica Bank, Meeder Asset Management Inc., Lazard Asset Management LLC, and Signaturefd LLC.

Maravai LifeSciences Holdings, Inc. provides products for the development of drug therapies, diagnostics, vaccines, and research on human diseases in the United States and internationally.

To hear what top-rated analysts currently recommend, MarketBeat suggests checking out their list of the five stocks to buy before the broader market catches on.

Find out more about top stock recommendations and where investors should put their money in uncertain markets with a free report from MarketBeat.



Read more: Traders Purchase Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI)